Основные параметры
P/S |
31.5 |
P/BV |
10.12 |
EV/EBITDA |
-5.83 |
EBITDA |
-0.0998 |
Цена ао |
12.3 |
Все параметры ⇨
Оценка
|
Недооценка
Название |
Значение |
Оценка |
P/S |
31.5 |
1 |
P/BV |
10.12 |
1 |
P/E |
|
0 |
EV/EBITDA |
-5.83 |
10 |
|
|
|
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
-31.53 |
1 |
ROE, % |
-96.96 |
1 |
|
|
|
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
|
0 |
DSI |
0 |
0 |
|
|
|
|
Долг
Название |
Значение |
Оценка |
Долг/EBITDA |
|
0 |
|
|
|
|
Импульс роста
Название |
Значение |
Оценка |
Рост прибыли, % |
0 |
0 |
Рост цены акции, % |
0 |
0 |
Рост дивидендов, % |
0 |
0 |
|
|
|
|
Основные владельцы
Institutions |
Объем |
Доля, % |
Jacob Asset Management Of New York LLC |
78000 |
0.14 |
CHI Advisors LLC |
1014840 |
1.8 |
Windmill Hill Asset Management Limited |
757891 |
1.35 |
Adams Chetwood Wealth Management LLC |
240968 |
0.43 |
Principal Global Investors, LLC |
997878 |
1.77 |
First Trust Portfolios L.P. |
10174 |
0.02 |
venBio Partners LLC |
1298191 |
2.31 |
Bayview Asset Management Co., Ltd. |
98700 |
0.18 |
Motif Capital Management, Inc |
950 |
0 |
Allianz Global Investors U.S. LLC |
19154 |
0.03 |
BlackRock Fund Advisors |
3982306 |
7.08 |
Global X Management Company LLC |
95122 |
0.17 |
Moloney Securities Asset Management |
342000 |
0.61 |
Integral Health Asset Management, LLC |
300000 |
0.53 |
SEI Investments Management Corp |
260225 |
0.46 |
State Street Global Advisors |
520610 |
0.93 |
Sio Capital Management, LLC |
355963 |
0.63 |
Allianz Global Investors |
30196 |
0.05 |
SSGA Funds Management Inc |
1826074 |
3.25 |
Lyxor International Asset Management S.A.S. |
94780 |
0.17 |
Содержится в ETF
Похожие компании
Описание Precision BioSciences, Inc.
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1\u002F2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R\u002FR multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.